삼성바이오로직스

Ensuring viral safety in large-scale manufacturing requires a deep understanding of intricate factors that affect virus filter performance. In our latest article, we explore how shifts in air diffusion values impact virus clearance in multi-round housings as well as the key considerations for effective risk assessment. Read here: https://lnkd.in/eJ-a4wHt #SamsungBiologics #VirusFiltration #MSAT #Manufacturing #ScaleUp

While antibody-drug conjugates (ADC) are emerging as a promising class of anti-cancer treatment, access to effective therapeutic agents remains limited. In this webinar, we delve into the importance of choosing high-quality payloads in ADC development and how our novel payload technologies can support increased efficacy and safety. Register now: https://lnkd.in/e_NgyJXh #ADC #payloads #linker_technology #webinar 

We proactively stay ahead of industry expectations by delivering on our capacity expansion commitments down to the month. With a current total manufacturing capacity of 604 kL, we are continuously expanding our scope to grow with our clients and stay on track with their timelines: https://lnkd.in/gZgm3Wtr #SamsungBiologics #Commitment #OnTrack #Capacity

Recent innovations in intensified fed-batch (IFB) processing have led to substantial improvements in cell culture yields and scalability to support efficient biopharmaceutical production. Watch this webinar, where our upstream process development scientists discuss the latest advancements in IFB processing and how our S-Tensify™ platform ensures consistent quality and productivity. https://lnkd.in/gau_f2Wm #SamsungBiologics #drugdevelopment #celldensity #cellculture #CLD #FedBatch

As biologics manufacturing can present unique challenges, partnering with a CDMO service provider with expertise and readily available capacity is crucial for success. Register for the Outsourced Pharma Capacity Update presentation on October 22 at 2PM (ET), where John Gagliardi, Senior Director of CMO Sales, will share insights on our enhanced manufacturing capabilities including N-1 perfusion technology and expansion into ADC. Register now: https://lnkd.in/eYy3v5Mb #SamsungBiologics #cdmo #Manufacturability #Perfusion #DP

Samsung Biologics has signed a record-breaking manufacturing deal with an Asia-based pharmaceutical company, a reflection of trusted and sustainable partnerships with our clients to help save patients around the world. By leveraging our innovative biomanufacturing technologies and proven expertise, we will continue our commitment to delivering high-quality biomedicines to the global market. Read more: https://lnkd.in/gkEVyG9c #SamsungBiologics #cdmo #manufacturing #partnership #deal

From cell line development to IND submission, Samsung Biologics has a track record of bringing fusion proteins and other complex molecules to preclinical testing. Deep understanding of a molecule based on a robust in-house database assures clients of timely solutions. Read the latest Newsroom story to discover our CDO services: https://lnkd.in/e8RRsmhW #SamsungBiologics #CDMO #CDO #ComplexMolecules

While multispecifics can present challenges in manufacturing due to their elaborate molecular structure, Samsung Biologics offers strengths in agility, flexibility, operational excellence, technology innovation, and timely capacity expansions to support clients’ complex manufacturing needs. Unlock the potential of your multispecific antibodies with advanced manufacturing technologies. Read here: https://lnkd.in/gcXrt9w2 #SamsungBiologics #Multispecific #Manufacturing

As a proud member of the Sustainable Markets Initiative Health Systems Task Force, Samsung Biologics is excited to announce the European Network on Climate & Health Education (ENCHE) was launched at the World Health Summit on October 14th. In collaboration with university partners from the University of Glasgow and Columbia University Mailman School of Public Health the Network brings together 25 European universities with the goal to equip over 10,000 medical students in an effort to integrate climate, health and sustainability curricula into medical training. Learn more about the Network and the support and momentum it has gathered from global health leaders here: https://lnkd.in/g59bAKdR #NetZero #ClimateHealth #WorldHealthSummit

Continuous biomanufacturing using N-1 perfusion comes with several benefits, such as improved efficiency and scalability. In this Fierce Pharma article, our MSAT experts Sungkeum Seo and Lalit Saxena discuss the advantages of perfusion technology and the strengths Samsung Biologics offers to reduce production time. Read more: https://lnkd.in/ea8Zeh-p #continuous #biomanufacturing #perfusion #technology #SamsungBiologics